Cantor Fitzgerald Reaffirms Overweight Rating for CG Oncology (NASDAQ:CGON)

Cantor Fitzgerald reissued their overweight rating on shares of CG Oncology (NASDAQ:CGON) in a report issued on Thursday, Benzinga reports. Cantor Fitzgerald currently has a $75.00 price target on the stock.

CGON has been the subject of a number of other research reports. HC Wainwright restated a buy rating and set a $75.00 price objective on shares of CG Oncology in a report on Thursday, April 4th. The Goldman Sachs Group assumed coverage on shares of CG Oncology in a research note on Tuesday, February 20th. They set a neutral rating and a $42.00 price target for the company. Finally, Morgan Stanley initiated coverage on CG Oncology in a report on Tuesday, February 20th. They set an overweight rating and a $55.00 price objective for the company.

CG Oncology Price Performance

NASDAQ:CGON traded down $3.23 during trading on Thursday, reaching $36.27. The company’s stock had a trading volume of 2,443,166 shares, compared to its average volume of 390,521. CG Oncology has a 12 month low of $28.55 and a 12 month high of $50.23. The company has a 50 day simple moving average of $39.63.

Institutional Investors Weigh In On CG Oncology

An institutional investor recently bought a new position in CG Oncology stock. BNP Paribas Financial Markets acquired a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON) during the first quarter, according to its most recent filing with the SEC. The fund acquired 11,198 shares of the company’s stock, valued at approximately $492,000. 26.56% of the stock is owned by institutional investors and hedge funds.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.